Archive for the ‘Gene Therapy Research’ Category

Gene Therapy Market Report Global analysis report is very helpful in understanding the Gene Therapy market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better. The current market is evolving its presence and some of the major players in the study areGlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc..

The Gene Therapy Market research study will give the answer to questions about the present performance of the market and the competitive scope, opportunity, challenges, cost, and more. The market can be divided based on product types and its sub-type, key applications, and major regions. Then it discusses recent product innovations and provides a scenario of potential regional market shares. It aims to fulfill your targeted customers understanding, needs, and wants as well as to explain how effectively a company can meet its requirements.

Note: *The Download PDF brochure only consists of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.

Request A PDF Sample Copy Gene Therapy Market Report Click here: https://www.coherentmarketinsights.com/insight/request-pdf/1774

Highlights of the Global Gene Therapy report:

Overall data will help improve clients competitive study, economic decision-making ability, as well as business planning, and the scope of futuristic developments in the global Gene Therapy market. The complex data is explained in a well-structured manner by the experts and for which they used various analytical techniques and represent the data in the form of graphs, flowcharts, and diagrams.

Important Facts About Gene Therapy Market Report:

The Gene Therapy industry report features different approaches and procedures endorsed by the market key players to make vital business decisions.

The keyword market depicts some parameters such as production value, Gene Therapy marketing strategy analysis, Distributors/Traders, and effect factors are also mentioned in this Gene Therapy Market research report.

This research report reveals Gene Therapy market overview, product overview, market share, supply chain analysis, demand and supply ratio, and import/export details.

Key Topics Covered in this Gene Therapy Market Study:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Market EcosystemMarket CharacteristicsMarket Segmentation Analysis

Part 05: Market Sizing

Gene Therapy Market DefinitionMarket SizingMarket Size And Forecast

Part 06: Five Forces Analysis

Bargaining Power of BuyersBargaining Power of SuppliersThe threat of New EntrantsThreat of SubstitutesThreat of RivalryMarket Condition

Part 07: Customer Landscape Part 08: Regional Landscape

Geographical SegmentationRegional ComparisonAmericas Market Size And ForecastEMEA Market Size And ForecastAPAC Market Size And Forecast

Part 09: Decision Framework Part 10: Drivers And Challenges

Market DriversMarket Challenges

Part 11: Market Trends Part 12: Vendor Landscape

OverviewLandscape DisruptionVendors CoveredVendor ClassificationMarket Positioning Of Vendors

Have Any Query? Ask Our Industry Expert @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1774

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Read more from the original source:
Covid-19 Impact On Gene Therapy Market to Perceive Substantial Growth with Top Players like GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune...

A new research report released by MarketsandResearch.biz with the title Global Gene Therapy Market Growth (Status and Outlook) 2020-2025covers the overall analysis of the market, detailing information about key players, sales, future trends, research findings, and current and future opportunities during 2020 to 2025 forecast period. The report significantly identifies the qualitative influence of various market factors on market segments and geographies. The report defines, segments the global Gene Therapy market and encompasses market potential, influential trends, and issues facing the market. The report categorizes segments the market on the basis of product type, application, technology, and region.

Market Rundown:

To offer more clarity regarding the industry, the report takes a closer look at the current status of different factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries. In the end, the report makes some important proposals for a new project of Gene Therapy market before evaluating its possibility. The report includes factors like industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The study offers business owners, stakeholders, and field marketing personnel with a significant evaluation of other factors such as demand and supply status, import and export, distribution channel, consumption volume, and production capability.

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Gene Therapy market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/61287

The market report covers the following companies: Bluebird Bio, Sangamo, Dimension Therapeutics, Avalanche Bio, Spark Therapeutics, Advantagene, Celladon, Vical Inc.,

Market segment by product type, along with their consumption (sales), market share and growth rate includes: Ex vivo, In Vivo,

Market segment by application, along with their consumption (sales), market share and growth rate covers: Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other

Furthermore, thoughts and opinions from companies and individuals in the report who are unbiased and less emotionally attached to recent developments, products, or services are listed in the report. Industry experts conducting the study further estimate the potential of the global Gene Therapy industry. According to the analysts, this information is important for firms looking to launch an innovative service or product on the market.

Market Segmentation By Region:

Further, in the report, analysis of the regional market information is covered by separating major different regions as, Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries). It focuses on analyzing the geographical subdivisions of the global Gene Therapy market based on factors such as key regions, with production, consumption, revenue (million USD), and market share and growth rate of the market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/61287/global-gene-therapy-market-growth-status-and-outlook-2020-2025

The Study Aims Are:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

See the original post here:
Global Gene Therapy Market 2020 Trends, Business Opportunities, Future Demand and Forecast 2025 - Cole of Duty

Prophecy Market Insights Gene Therapy market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Gene Therapy market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Gene Therapy report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/39

The Gene Therapy research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Gene Therapy market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Gene Therapy market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Gene TherapyMarket Key Companies:

GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc.

Segmentation Overview:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Gene Therapy market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/39

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Gene Therapy market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Read this article:
Gene Therapy Market: Predictable To Witness Sustainable Evolution over 2020-2030 - Cole of Duty

DUBLIN--(BUSINESS WIRE)--The "Global CRISPR Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

The global CRISPR market is estimated to expand at a CAGR of 23.95% over the forecasting period 2019-2028.

The increasing lifestyle-oriented diseases, the rising prevalence of genetic diseases and the growing application of drugs are the primary factors driving the growth of the CRISPR market. In addition, the increasing geriatric population and the rising incidence of genetic ailments are also likely to lead to an increase in demand for global CRISPR technology.

However, ethical issues associated with the technology and the changing regulatory environment is restraining the market. The market is also challenged by the availability of alternate technologies and the lack of awareness regarding CRISPR. But, the advancements in the gene-based therapy application and the increased demand for CRISPR will create market opportunities.

The global market report covers the countries from North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Asia-Pacific is likely to be the fastest-growing for the CRISPR market in the world. With the rapidly advancing technological developments and the wide range of applications of CRISPR technology in countries like India and China, regional growth is expected in the next few years. China has already started various gene-editing research work focusing on the CRISPR technology market.

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/so6ult

Continue reading here:
Global CRISPR Market (2019 to 2028) - Advancements in the Applications of Gene-Based Therapy Presents Opportunities - ResearchAndMarkets.com -...

-New Data Highlights the Flexibility of OncoSec's Therapeutic Platform to Enable Greater Anti-Tumor Activity with the Next-Generation TAVOPLUSIL-12 Plasmid

PENNINGTON, N.J. and SAN DIEGO, June 22, 2020 /PRNewswire/ --OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12 (IL-12) plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9). These product candidates, coupled with the new low-voltage electroporation gene delivery system, represent a promising approach for treating patients with a variety of solid tumors.The data were presented today during two late-breaking poster presentations at the American Association for Cancer (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.

"Multiple studies haveused intratumoral plasmid IL-12 (TAVO)to treat solid tumor indications with a demonstrable clinical benefit due to thiscytokine's ability to drive deep and durable immune responses," said Christopher Twitty, Ph.D., OncoSec's Chief Science Officer. "The new preclinical data exhibited in both AACR presentations highlights the evolution of OncoSec's IL-12-based platform. Incorporation of a chemokine gradient and a polyclonal T cell stimulator with the enhanced IL-12 backbone of TAVOPLUS holds significant potential in the treatment of solid tumors. We believe these data provide a strong rationale for filing an Investigational New Drug application and we are excited to advance TAVOPLUS into clinical development."

The following posters were presented during the session titled, "Late-Breaking Research: Immunology 2":

Title:"Intratumoral electroporation of plasmid-encoded IL-12 and membrane-bound anti-CD3 increases tumor immunogenicity and augments the function of T cell subsets"Poster Number:14Abstract Number:LB-390

Study Highlights:

Compared to IT-tavo-EP, TAVO+-CD3 enhances T cells engagement with tumor cells and augments T cell killing function in preclinical cancer models by:

Title:"Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of CXCL9 synergizes with IL-12 gene therapy (TAVO) to elicit robust anti-tumor immunity"Poster Number:20Abstract Number:LB-396

Study Highlights:

The full abstracts presented at the AACR Virtual Meeting II are available online at http://www.aacr.org and the posters are available on OncoSec's website at http://www.oncosec.com.

About OncoSec Medical IncorporatedOncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with the anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in two KEYNOTE clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 trial in metastatic triple negative breast cancer. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its novel Visceral Lesion Applicator designed to target deep internal lesions, such as liver, lung or pancreatic lesions. For more information, please visitwww.oncosec.com.

TAVOis a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking StatementsThis release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials, the allowance by FDA of the clinical use of CORVax12 and our next-generation APOLLO generator in this or any future clinical trials, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's websitewww.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Company Contact:Gem HopkinsHead of Corporate Communications858-210-7334[emailprotected]

SOURCE OncoSec Medical Incorporated

http://www.oncosec.com

View post:
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II -...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the ophthalmology therapeutics market and it is poised to grow by USD 10.42 billion during 2020-2024, progressing at a CAGR of almost 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increase in prevalence of eye diseases has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. https://www.technavio.com/report/report/ophthalmology-therapeutics-market-industry-analysis

Ophthalmology Therapeutics Market 2020-2024: Segmentation

Ophthalmology Therapeutics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40882

Ophthalmology Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The ophthalmology therapeutics market report covers the following areas:

This study identifies the development of novel drug delivery systems as one of the prime reasons driving the ophthalmology therapeutics market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Ophthalmology Therapeutics Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Assessment of COVID-19's Effect on Ophthalmology Therapeutics Market 2020-2024 | Increase in Prevalence of Eye Diseases to Augment Growth | Technavio...

Prophecy Market Insights Personalized Gene Therapy Treatment market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Personalized Gene Therapy Treatment market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Personalized Gene Therapy Treatment report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/61

The Personalized Gene Therapy Treatment research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Personalized Gene Therapy Treatment market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Personalized Gene Therapy Treatment market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Personalized Gene Therapy TreatmentMarket Key Companies:

Amgen, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., SynerGene Therapeutics, Inc., Cold Genesys, Inc., Bellicum Pharmaceuticals, Inc., Takara Bio, Inc.,Ziopharm Oncology, Inc., , Sevion Therapeutics, Inc., OncoSec Medical, Inc., and Burzynski Clinic.

Segmentation Overview:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Personalized Gene Therapy Treatment market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/61

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Personalized Gene Therapy Treatment market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Read the original here:
2020 Prediction for Personalized Gene Therapy Treatment market: Key Players and Driving Factors Analysis - Cole of Duty

Pancreatic tumors employ multiple strategies for evading treatment, making them quick to spread and difficult to treat effectively. At this weeks virtual meeting of the American Association for Cancer Research (AACR), several research groups are presenting new therapeutic tactics aimed at interrupting survival pathways in pancreatic cancer.

A research team led by the University of Minnesota is investigating a combination of blocking both the immune checkpoint PD-L1 and CD40, a cell-surface molecule that also moderates the immune response to cancer. In mouse models of pancreatic cancer, either therapy alone prolonged survivalbut the tumors recurred in 100% of the animals. The researchers found tumor escape variants in key genes.

When the team tested a combination of PD-L1 and CD40 blockade, 60% of the mice were cured, the researchers reported at AACR.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

They went on study gene expression in the tumors of the animals that received the combination treatment. They discovered an accumulation of tumor-specific T cells capable of eradicating pancreatic tumors. Whats more, the anti-PD-L1 and anti-CD40 combination prompted an accumulation of memory T cells in the pancreascells that could be critical for preventing recurrences. They plan to discuss the findings in detail on Wednesday.

CD40 is a popular target for researchers investigating cancer combination treatments. Roche, for example, is testing its CD40 drug, selicrelumab, in combination with its PD-L1 blocker Tecentriq in solid tumors.

RELATED: An immuno-oncology triplet from Roche shows promise in mouse models of several tumors

Tyme Technologies is pursuing a different strategy for preventing tumor escapeone that hinges on cancer metabolism. Its drug, SM-88 (racemetyrosine), is designed to alter protein synthesis, increase oxidative stress and change other metabolic factors in ways that hamper the ability of the cancer cells to survive.

Tyme used cell lines and mouse models to characterize the anti-cancer effects of SM-88, which is currently being tested in a pivotal clinical trial in metastatic pancreatic cancer.

At the AACR virtual conference, Tyme reported that SM-88 disrupted autophagy in two types of pancreatic cancer cells. Autophagy is the process by which cells recycle waste products so they can survive.

In mouse models of pancreatic cancer, the drug reduced levels of regulatory T lymphocytes and M2 macrophagescells that suppress the immune response to cancerTyme showed in a poster presentation (PDF).

Tyme has started a phase 2/3 trial that will combine SM-88 with three other treatments in patients with metastatic pancreatic cancer who have failed two previous lines of therapy.

Excerpt from:
AACR: Attacking pancreatic cancer by thwarting its survival strategies - FierceBiotech

TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying established metastatic cervical and breast cancer (p=0.001; p=0.002). Data are presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held June 2224, 2020.

"Identifying a tumor-specific target is a key step for developing precise and safe immunotherapy for cancer, and MOSPD2 may be an ideal target. Our new data provide in-vitro and in-vivo proof-of-concept for the potential of VBL's novel MOSPD2 bi-specific antibody candidates for immuno-oncology mediated therapy for solid tumors," said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.

VBL's research has identified MOSPD2 as a protein involved in cell motility, whose expression is highly elevated in various solid tumors. The proprietary bi-specific antibody candidates developed by VBL have two separate arms one arm binds to MOSPD2 on tumor cells and the second recruits host T-cells that attack the tumor. The data presented today demonstrate that the company's bi-specific antibody candidates: 1) mediated killing of tumor cells by CD8 T-cells in a dose-dependent manner; 2) induced T-cell activation in-vivo; and 3) extended survival of tumor-bearing animals. The results highlight the potential of MOSPD2-mediated immuno-oncology therapy for the treatment of various solid tumors.

For VBL's poster presentations at AACR kindly see the following links:LB-poster and Poster2

About VBL's VB-600 PlatformVBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 investigational monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored all comers phase 1 trial as well as in three VBL-sponsored tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including MOSPD2, including their clinical development, therapeutic potential and clinical results and the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

Excerpt from:
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of...

Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing

Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today presentations of preclinical findings on the gene editing of natural killer (NK) cells and therapeutic combinations of engineered NK cells and T cells. The findings were presented in two posters at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II.

As we advance our two co-lead programs for engineered NK cells targeting NKG2D ligands and CD19, Nkarta continues to pioneer novel development approaches that leverage our platform capabilities in NK cell expansion, targeting, manufacturing and cryopreservation, said Paul J. Hastings, President and Chief Executive Officer of Nkarta. The findings presented today highlight the exciting potential of gene editing to add additional punch to the tumor killing properties of engineered NK cells and address the inhibitory checkpoints of the tumor microenvironment. In addition, we are encouraged by the early observation of beneficial effects when CAR NK cells and CAR T cells are combined as a potential NK Plus T anti-cancer therapeutic.

The exciting data generated by our scientists support our optimism about gene editing and immune cell combinations further propelling our pipeline of NK cell therapies, said James Trager, Chief Scientific Officer of Nkarta. These laboratory advances shine a light on the mechanisms behind the anti-cancer immune response. Were looking forward to learning more from our planned clinical studies about the most relevant ways to optimize NK cell performance using these approaches.

The posters are available on the AACR Virtual 2020 Annual Meeting II website and the Presentations section of the Nkarta website.

Details of Posters

Title: CRISPR-Cas9-gRNA RNP mediated gene knockout of TGFbR2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGFb

Poster number: 891 / 20

Session: PO.IM02.01 Adoptive Cell Therapy 1

Presentation time: June 22, 2020, 9:00am 6:00pm ET

Summary: An optimized CRISPR/Cas9 gene editing system was used successfully in engineered CAR NK cells to disrupt TGFbR2 and CISH, genes related to the downregulation of cytokine signaling and immune cell activation. TGFbR2 knockout CAR NK cells were resistant to TGFb-mediated inhibition of tumor cell killing. CISH knockout CAR NK cells had improved proliferation, survival, cytokine production and tumor cell killing. The findings showed that gene editing can be combined with engineering to enhance NK cell function and resist the inhibitory action of the tumor microenvironment.

Title: A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation

Poster number: 4235 / 9

Session: PO.CL06.02 Adoptive Cell Therapy 4 / Combination Immunotherapies

Presentation time: June 22, 2020, 9:00am 6:00pm ET

Summary: A novel platform combining CAR-NK and CAR-T cells enhanced anti-tumor cytotoxicity and persistence, lowered the accumulation of cytokines associated with cytokine release syndrome, promoted NK cell expansion while reducing antigen dependent proliferation of T cells, and prevented tumor relapse in an animal model for at least four months.

About Nkarta

Nkarta, Inc. focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkartas mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients. Founded in 2015, the companys investors include Amgen Ventures, Deerfield Management, LSP, Logos Capital, NEA, Novo Holdings A/S, RA Capital Management, Samsara BioCapital and SR One. For more information, please visit the companys website atwww.nkartatx.com.

Contact:

Greg MannNkarta, Inc.gmann@nkartatx.com

Sylvia WheelerWheelhouse Communicationsswheeler@wheelhouselsa.com

Continued here:
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at...

Dublin, June 22, 2020 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Region Coverage:

Company Coverage:

Regenerative medicines emphasise on the regeneration or replacement of tissues, cells or organs of the human body to cure the problem caused by disease or injury. The treatment fortifies the human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimer's, diabetes, Parkinson's, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Key Topics Covered:

1. Executive Summary

2. Introduction2.1 Regenerative Medicine: An Overview2.2 Regeneration in Humans: An Overview2.3 Expansion in Peripheral Industries of Regenerative Medicine2.4 Approval System for Regenerative Medicine Products2.5 Regenerative Medicine Segmentation

3. Global Market Analysis3.1 Global Regenerative Medicine Market: An Analysis3.1.1 Global Regenerative Medicine Market by Value3.1.2 Global Regenerative Medicine Market by Products (Cell Therapy, Tissue Engineering, Gene Therapy and Small Molecules and Biologics)3.1.3 Global Regenerative Medicine Market by Material (Biologically Derived Material, Synthetic Material, Genetically Engineered Materials and Pharmaceuticals)3.1.4 Global Regenerative Medicine Market by Region (North America, Europe, Asia Pacific and ROW)

3.2 Global Regenerative Medicine Market: Product Analysis3.2.1 Global Cell Therapy Regenerative Medicine Market by Value3.2.2 Global Tissue Engineering Regenerative Medicine Market by Value3.2.3 Global Gene Therapy Regenerative Medicine Market by Value3.2.4 Global Small Molecules and Biologics Regenerative Medicine Market by Value

3.3 Global Regenerative Medicine Market: Material Analysis3.3.1 Global Biologically Derived Material Market by Value3.3.2 Global Synthetic Material Market by Value3.3.3 Global Genetically Engineered Materials Market by Value3.3.4 Global Regenerative Medicine Pharmaceuticals Market by Value

4. Regional Market Analysis4.1 North America Regenerative Medicine Market: An Analysis4.2 Europe Regenerative Medicine Market: An Analysis4.3 Asia Pacific Regenerative Medicine Market: An Analysis4.4 ROW Regenerative Medicine Market: An Analysis

5. COVID-195.1 Impact of Covid-195.2 Response of Industry to Covid-195.3 Variation in Organic Traffic5.4 Regional Impact of COVID-19

6. Market Dynamics6.1 Growth Drivers6.1.1 Growth in Geriatric Population6.1.2 Rising Global Healthcare Expenditure6.1.3 Increasing Diabetic Population6.1.4 Escalating Number of Cancer Patients6.1.5 Rising Prevalence of Cardiovascular Disease6.1.6 Surging Obese Population6.2 Challenges6.2.1 Legal Obligation6.2.2 High Cost of Treatment6.3 Market Trends6.3.1 3D Bio-Printing6.3.2 Artificial Intelligence to Advance Regenerative Medicine

7. Competitive Landscape7.1 Global Regenerative Medicine Market Players: A Financial Comparison7.2 Global Regenerative Medicine Market Players' by Research & Development Expenditure

8. Company Profiles8.1 Bristol Myers Squibb (Celgene Corporation)8.1.1 Business Overview8.1.2 Financial Overview8.1.3 Business Strategy8.2 Medtronic Plc8.2.1 Business Overview8.2.2 Financial Overview8.2.3 Business Strategy8.3 Smith+Nephew (Osiris Therapeutics, Inc.)8.3.1 Business Overview8.3.2 Financial Overview8.3.3 Business Strategy8.4 Novartis AG8.4.1 Business Overview8.4.2 Financial Overview8.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/w15smu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original here:
Outlook on the Worldwide Regenerative Medicine Industry to 2024 - Rising Global Healthcare Expenditure Presents Opportunities - GlobeNewswire

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Go here to see the original:
What's this? A rival bidder heads back to the table with a better offer for Tetraphase. Antibiotics show faint signs of life - Endpoints News

CMI presents an in-depth overview of the Global Viral Vectors and Plasmid DNA Manufacturing Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics..

This study focuses on the Global Viral Vectors and Plasmid DNA Manufacturing market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Viral Vectors and Plasmid DNA Manufacturing growth in Key regions. In order to provide valuable insight by each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request A Sample Copy Viral Vectors and Plasmid DNA Manufacturing Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/962

The Global Viral Vectors and Plasmid DNA Manufacturing is segmented by:

By Product Type: Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report includes Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Enquire here get customization & check discount, please click: https://www.coherentmarketinsights.com/insight/request-discount/962

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Viral Vectors and Plasmid DNA Manufacturing Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Analysis of M&As, Partnership & JVs in Global Viral Vectors and Plasmid DNA Manufacturing Industry in the United States & Other Emerging Geographies

Top 10 Global Viral Vectors and Plasmid DNA Manufacturing Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Viral Vectors and Plasmid DNA Manufacturing MARKET LANDSCAPE

Market EntropyMarket segmentation analysisMarket characteristics

PART 06: Global Viral Vectors and Plasmid DNA Manufacturing MARKET SIZING

Market definitionMarket size and forecastMarket sizing

PART 07: Global Viral Vectors and Plasmid DNA Manufacturing MARKET SEGMENTATION

SegmentationMarket opportunityComparison

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Excerpt from:
Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Growth Analysis by Segmentation, Industry Size, Global Opportunities and Regional...

DUBLIN, June 22, 2020 /PRNewswire/ -- The "Nucleic Acid Isolation and Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Precision Medicine), End User (Academic) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global nucleic acid isolation and purification market is projected to reach USD 4.8 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 8.9% during the forecast period.

The major factors driving the growth of the market include increasing R&D activities as well as technological advancements and increasing automation. However, the high cost of automated instruments is expected to hinder the growth of the market.

The instruments segment will grow at the highest rate during the forecast period.

On the basis of product, the nucleic acid isolation and purification market are segmented into kits, reagents, and instruments. In 2019, kits were the largest product segment in the market. Growth in this market can be attributed to the continuous focus of key market players on developing and launching new and advanced kits. However, the instruments segment is expected to grow at the highest rate during the forecast period.

By type, the plasmid DNA isolation and purification segment accounted for the largest share of the nucleic acid isolation and purification market in 2019.

On the basis of type, the global nucleic acid isolation and purification market are segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. The plasmid DNA isolation segment accounted for the largest share of the nucleic acid isolation and purification market in 2019. The large share of this market segment can be attributed to the wide use of purified plasmid DNA in a variety of downstream applications, such as PCR, sequencing, expression of proteins, gene therapy, and transfection.

The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2025).

North America accounted for the largest share of the nucleic acid isolation and purification market in 2019. Significant R&D spending in biotechnology and pharmaceutical companies, the large size of the biotechnology industry, technological advancements, and government support in the region are the key factors driving the growth of the nucleic acid isolation and purification market in North America. On the other hand, the Asia Pacific is projected to register the highest growth during the forecast period. This large share can be attributed to factors such as the increasing number of genomic projects and increasing R&D investments by pharmaceutical & biotechnology companies in this region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Nucleic Acid Isolation and Purification Market Overview 4.2 North America: Nucleic Acid Isolation and Purification Market, by Product (2019) 4.3 Geographical Snapshot of the Nucleic Acid Isolation and Purification Market

5 Market Overview 5.1 Market Dynamics 5.1.1 Drivers 5.1.1.1 Increasing R&D Activities 5.1.1.2 Technological Advancements and Increasing Automation 5.1.2 Restraints 5.1.2.1 High Cost of Automated Instruments 5.1.3 Opportunities 5.1.3.1 High Scope of Growth in Emerging Economies 5.1.3.2 Improving Regulatory and Reimbursement Scenario 5.1.3.3 Molecular Diagnostics and Personalized Medicine 5.1.4 Trends 5.1.4.1 Impact of the Covid-19 Pandemic 5.1.4.2 Increase in Government Funding

6 Nucleic Acid Isolation and Purification Market, by Product 6.1 Introduction 6.2 Kits 6.2.1 Kits Were the Largest Product Segment in the Market in 2019 6.3 Reagents 6.3.1 Reagents Segment to Grow at a Steady Rate During The Forecast Period 6.4 Instruments 6.4.1 Automated Instruments Enable a Faster, Cleaner, and More Consistent Nucleic Acid Extraction Process

7 Nucleic Acid Isolation and Purification Market, by Method 7.1 Introduction 7.2 Column-Based Isolation and Purification 7.2.1 Column-Based Isolation and Purification Was the Largest Segment in the Market in 2019 7.3 Magnetic Bead-Based Isolation and Purification 7.3.1 Magnetic Bead-Based Isolation and Purification Segment to Register the Highest CAGR During the Forecast Period 7.4 Reagent-Based Isolation and Purification 7.4.1 Reagent-Based Isolation and Purification Segment to Register Steady Growth During the Forecast Period 7.5 Other Isolation and Purification Methods

8 Nucleic Acid Isolation and Purification Market, by Type 8.1 Introduction 8.2 Plasmid Dna Isolation and Purification 8.2.1 Plasmid Dna Isolation and Purification Accounted for the Largest Share of the Market 8.3 Total Rna Isolation and Purification 8.3.1 Total Rna Isolation and Purification Segment to Register Steady Growth 8.4 Genomic Dna Isolation and Purification 8.4.1 Genomic Dna Isolation is the First Step in Genetic-Based Tests 8.5 Messenger Rna Isolation and Purification 8.5.1 Messenger Rna Isolation and Purification is Mainly Used in the Study of Gene Expression and Transcriptomics 8.6 Circulating Nucleic Acid Isolation and Purification 8.6.1 Clinical Applications to Drive the Market for Circulating Nucleic Acid Isolation and Purification 8.7 Microrna Isolation and Purification 8.7.1 Microrna Kits Provide Rapid Isolation and Purification of Rna Molecules from Samples 8.8 Pcr Cleanup 8.8.1 Time-Consuming Laboratory Procedures to Limit the Growth of this Market During the Forecast Period 8.9 Other Nucleic Acid Isolation and Purification Types

9 Nucleic Acid Isolation and Purification Market, by Application 9.1 Introduction 9.2 Diagnostics 9.2.1 Diagnostic Applications Form the Largest and Fastest-Growing Segment in the Market 9.3 Drug Discovery & Development 9.3.1 Ngs Benefits Drug Discovery Applications in Various Therapeutic Areas 9.4 Personalized Medicine 9.4.1 Rising Incidence of Cancer and Increasing Research and Funding to Drive the Market for this Segment 9.5 Agriculture & Animal Research 9.5.1 Favorable Funding Scenario to Support Market Growth 9.6 Other Applications

10 Nucleic Acid Isolation and Purification Market, by End-user 10.1 Introduction 10.2 Hospitals & Diagnostic Centers 10.2.1 Availability of Genetic Tests and Rising Focus on Personalized Medicine in Hospitals to Drive Market Growth 10.3 Academic & Government Research Institutes 10.3.1 Increase in Research Intensity to Drive the Usage of Nucleic Acid Isolation and Purification Systems 10.4 Pharmaceutical & Biotechnology Companies 10.4.1 Increasing Number of Research Projects in Genomics and Related Areas is Expected to Drive the Market 10.5 Contract Research Organizations 10.5.1 Contract Research Organizations Are Expected to Register Steady Growth During the Forecast Period 10.6 Other End-users

11 Nucleic Acid Isolation and Purification Market, by Region 11.1 Introduction11.2 North America11.2.1 US11.2.1.1 Government and Private Funding to Support Market Growth in the Us11.2.2 Canada11.2.2.1 Demand for Nucleic Acid Isolation and Purification in Canada is Increasing Primarily Due to Growing Investments in Genomics11.3 Europe11.3.1 Germany11.3.1.1 Germany is the Largest Market for Nucleic Acid Isolation and Purification in Europe11.3.2 UK11.3.2.1 Government Support for Research in the Form of Investments, Funds, and Grants to Support Market Growth11.3.3 France 11.3.3.1 High Cancer Burden in France to Drive Market Growth 11.3.4 Roe 11.4 Asia-Pacific 11.4.1 China 11.4.1.1 China to Register the Highest Growth in the Nucleic Acid Isolation and Purification Market in APAC 11.4.2 Japan 11.4.2.1 Japan to Register Steady Growth During the Forecast Period 11.4.3 India 11.4.3.1 Strong Growth Trends in the Pharmaceutical & Biotechnology Industries to Drive the Market in India 11.4.4 Roapac 11.5 Rest of the World 11.5.1 Latin America 11.5.1.1 to Prevent Cancer Mortality, the Brazilian Government Recommends Screening Programs for Breast and Prostate Cancer 11.5.2 Middle East & Africa 11.5.2.1 Lack of Infrastructure for Research to Hamper the Growth of the Naip Market in the Middle East & Africa

12 Competitive Landscape 12.1 Introduction 12.2 Market Evaluation Framework 12.3 Revenue Analysis of Top Market Players 12.4 Competitive Scenario 12.4.1 Collaborations & Agreements 12.4.2 Product Launches & Approvals 12.4.3 Acquisitions 12.4.4 Expansions

13 Company Evaluation Matrix and Company Profiles 13.1 Company Evaluation Matrix 13.1.1 Market Share Analysis 13.2 Competitive Leadership Mapping (Overall Market) (2019) 13.2.1 Stars13.2.2 Emerging Leaders 13.2.3 Pervasive Players 13.2.4 Emerging Companies

14 Company Profiles 14.1 Qiagen N.V. 14.2 Thermo Fisher Scientific 14.3 F. Hoffman-La Roche AG 14.4 Promega Corporation 14.5 Agilent Technologies 14.6 Bio-Rad Laboratories 14.7 Danaher Corporation 14.8 GE Healthcare 14.9 Illumina 14.10 Merck Kgaa 14.11 Takara Bio, Inc. 14.12 New England Biolabs 14.13 Zymo Research 14.14 Norgen Biotek 14.15 Omega Bio-Tek, Inc. 14.16 Other Companies 14.16.1 Genaxxon Bioscience GmbH 14.16.2 3B Blackbio Biotech India Ltd. 14.16.3 Invitek Molecular GmbH 14.16.4 Biovision 14.16.5 Analytik Jena AG

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ra5qde

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:
$4.8 Billion Worldwide Nucleic Acid Isolation and Purification Industry to 2025 - Impact of COVID-19 Pandemic - PRNewswire

A new research study has been presented by Precision Market Reports (PMR) after a comprehensive analysis on CELL CULTURE MEDIA Market where user can get benefits from the complete market research report with all required useful information on market. Report discuss all major market aspects with expert opinion on current market status along with historic data as well. Detailed study Price, Share, Size & Growth, Latest News & Developments, Expansion Plan, Current Business Strategy, Top Companies, Sales, Revenue & Competitors Analysis, Production and Consumption, Demand & Supply, Industry and Business Study, Effect of Covid 19 (Buyers & Sellers) and Prediction 2020-2025.

Regions Covered in the CELL CULTURE MEDIA Market:

Covid-19 Scenario:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the corona virus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Top Players & Competitive Analysis (Benefits) for CELL CULTURE MEDIA:

A competitive analysis is a strategy where we identify major competitors and research their products, sales, and marketing strategies. By doing this, you can create solid business strategies that improve upon your competitors. A competitive analysis helps you learn the ins and outs of how your competition works. It also helps you identify what theyre doing right and opportunities where you can easily one-up them by using a strategy they havent taken advantage of.Every brand can benefit from regular competitor analysis. By performing a competitor analysis, youll be able to:

As you can see, learning any of these four components will lead your brand down the path of achievement. But before you get too excited to start, we need to nail down a few important basics.

Once you identify your true competition, youll need to determine what metrics youll be comparing across the board. Below, well give nine specific factors to compare and tips on how to identify this competition in the first place.

CELL CULTURE MEDIA Competitors Analysis includes market shares for all the companies listed below, Competitors Analysis revenue chart, Competitive Dashboard, and the competitors latest strategies for overcoming the Covid 19 pandemic situation.

Get A PDF Sample of CELL CULTURE MEDIA Report: https://www.precisionmarketreports.com/download-sample/294015

SEGMENTAL ANALYSIS:

Business segment reporting breaks out a companys financial data by company divisions,subsidiaries, or other kinds of businesssegments. In an annual report, business segment reporting provides an accurate picture of apublic companysperformance to its shareholders. Management uses business segment reporting to evaluate the income, expenses, assets, and liabilities of each business division to assess its general healthincluding profitability and potential pitfalls.

Asegmentis a component of a business that generates its ownrevenuesand creates its own product, product lines, or service offerings.In general, if a unit of a business can be lifted out of the larger company and remain a self-sufficient entity, then it may be classified as a business segment.

By ApplicationBiopharmaceutical Manufacturing, Tissue Culture & Engineering, Gene Therapy, Cytogenetic

By TypeClassical Media & Salts, Serum-free Media, Stem Cell Media

By Life TechnologiesBD, Thermo Fisher, Corning (Cellgro), Lonza, Sigma-Aldrich, Takara, GE Healthcare, Merck Millipore, HiMedia

By CellGenixZenbio, Atlanta Biologicals, PromoCell

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

KEY TAKEAWAYS:

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) @: https://www.precisionmarketreports.com/download-sample/294015

What Reports Provides:

Table of Contents:

1.1 Research Scope

1.2 Market Segmentation

1.3 Research Objectives

1.4 Research Methodology

1.4.1 Research Process

1.4.2 Data Triangulation

1.4.3 Research Approach

1.4.4 Base Year

1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.5.2 Covid-19 Impact: Commodity Prices Indices

1.5.3 Covid-19 Impact: Global Major Government Policy

1.6 The Covid-19 Impact on CELL CULTURE MEDIA Industry

1.7 COVID-19 Impact: CELL CULTURE MEDIA Market Trends

2 GLOBAL CELL CULTURE MEDIA QUARTERLY MARKET SIZE ANALYSIS

2.1 CELL CULTURE MEDIA Business Impact Assessment COVID-19

2.1.1 Global CELL CULTURE MEDIA Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2020-2025

2.2 Global CELL CULTURE MEDIA Quarterly Market Size 2020-2021

2.3 COVID-19-Driven Market Dynamics and Factor Analysis

2.3.1 Drivers

2.3.2 Restraints

2.3.3 Opportunities

2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

3.1 By Players, Global CELL CULTURE MEDIA Quarterly Market Size, 2019 VS 2020

3.2 By Players, CELL CULTURE MEDIA Headquarters and Area Served

3.3 Date of Key Players Enter into CELL CULTURE MEDIA Market

3.4 Key Players CELL CULTURE MEDIA Product Offered

3.5 Mergers & Acquisitions, Expansion Plans

Any query? Enquire Here for Discount (COVID-19 Impact Analysis Updated Sample): https://www.precisionmarketreports.com/download-sample/294015

The study points out the limitations that aim to overcome the challenges to massive success for companies. Through means of this study, customers can conveniently obtain views on the CELL CULTURE MEDIA market based on the current scenario.

What is the Impact of Covid-19 Outbreak on the Online Remote Proctoring (Remote Invigilation)?

About Precision Market Reports (PMR):

Precision Market Reports provides quantified B2B research on 25,000 high-growth niche opportunities / threats that will impact 50 to 75 percent of global company revenues. Actively representing more than 5000 customers worldwide, including 50 percent of Fortune 500 global businesses as clients. Almost 25,000 top officials across eight industries worldwide approach Precision Market Reports for their pain points around revenue decisions.

Our reports provide a rare combination of concrete perspectives and qualitative research to help businesses attain sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile extensive, interspersed with relevant data, market studies.

Precision Business Reports provide objective insight and reliable data, helping companies of all sizes take timely decisions. We tailor creative solutions for our customers to help them address problems that are distinct from their business. Our aim is to empower our customers with holistic market intelligence, giving them a granular overview of the market in which they operate.

Contact Person:Mr.Brian SmithPrecision Market Reports169, Elisenthal,North Rhine- Westphalia, Rhehin- Sieg- Kreis,Windeck, Hohnrath,Germany, DE- 51570.Phone:+1 (845) 377-0269Website:www.precisionmarketreports.comEmail:[emailprotected]/[emailprotected]

Read the original here:
Global Covid-19 impact on CELL CULTURE MEDIA Market 2020 Latest Technology, Size, Growth Opportunities, Research Analysis and Forecast - Cole of Duty

Ahead of a planned Phase III study, Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.

This morning, the two companies updated results from a December 2019 announcement that showed a high dose treatment of the gene therapy giroctocogene fitelparvovec generated sustained factor VIII activity levels in five patients. Hemophilia A is a genetic bleeding disorder where missing or faulty blood clotting factor VIII prevents blood from clotting normally. The clotting failure can cause frequent and spontaneous bleeding that can lead to long-term joint damage and disability. For hemophilia A patients who do not have factor VIII inhibitors, typical treatment required multiple infusions of factor VIII replacements each week.

In the Alta study, the updated data showed the patients who received the 3e13 vg/kg dose produced the all-important protein on their own. No patients in the study experienced bleeding events or required FVIII infusions, Pfizer and Sangamo announced this morning. The factor VIII activity levels reflect measurements up to 61 weeks, which is based on follow-up data from the longest-treated patient in the cohort. The updated data was presented as a late-breaking oral abstract at the World Federation of Hemophilia 2020 World Congress.

Seng Cheng, chief scientific officer of Pfizers Rare Disease Research Unit, touted the results and said the research team is encouraged by the potential of the gene therapy to provide a long-term solution to hemophilia A patients. Giroctocogene fitelparvovec uses a recombinant adeno-associated virus serotype 6 vector (AAV6) encoding the complementary deoxyribonucleic acid for B domain deleted human FVIII. Pfizer and Sangamo plan to begin dosing patients with the gene therapy in the Phase III trial later this year, Cheng added.

Adding to the potential of giroctocogene fitelparvovec in this indication, Bettina M. Cockroft, chief medical officer of Sangamo, said the treatment offers a new approach to treating the disease and has the potential to provide a one-time treatment that would enable patients to produce the missing factor on their own.

These follow-up data indicate that treatment with giroctocogene fitelparvovec resulted in sustained factor levels up to 14 months following treatment and suggests the potential of this investigational gene therapy to alleviate the treatment burden of current hemophilia disease management, Cockroft said in a statement.

The therapy was generally well-tolerated, although one patient who received the high dose had a treatment-related serious adverse event that was resolved within a day. Four of the five received corticosteroids for elevated liver enzymes and three patients had subsequent ALT elevations that responded to corticosteroids.

Data for the Phase I/II study was initially presented at the American Society of Hematology annual meeting in December. Data presented at that time showed that giroctocogene fitelparvovec was generally well tolerated and resulted in sustained FVIII levels up to 44 weeks, the extent of follow-up for the longest-treated patient in the 3e13 vg/kg dose cohort at that time. Pfizer and Sangamo plan to present further follow-up data from the Alta study when all five patients in the 3e13 vg/kg dose cohort have been followed for at least one year.

Pfizer released its data a day after BioMarin showcased Phase I/II data from its gene therapy study in hemophilia A. The U.S. Food and Drug Administration is reviewing the biologics license application for BioMarins gene therapy under Priority Review, with potential action in August.

More here:
Pfizer and Sangamo Release Updated Gene Therapy Data in Hemophilia A - BioSpace

Gene Therapy is a rapidly expanding market within the global biotechnology industry. Using techniques such as CRIPSR, a gene editing technology, the aim is to treat and prevent diseases. By inserting or altering harmful genes in a patient cell, it can reduce the need for surgeries or drugs.

The UK is at the forefront of advancing Gene Therapy technology accounting for 12% of global gene and cell trials [1]. Innovation hubs such as those in White City, London and Stevenage have spearheaded this development.

To carry out this experimental work, companies require specialist systems and infrastructure. Biopharma recently installed 10 Premium 212 Microbiological Safety cabinets to a Gene Therapy company based in white City, London. This is now the second company within the emerging hub of innovative life sciences start-ups to install Faster safety cabinets.

A Microbiological safety cabinet provides product, personnel and environmental protection while handling biological samples such as in tissue culture, biological testing and pathogenic samples.

The ambient air is drawn in from the slots at the stainless-steel base of the front opening and it then passes under the work surface, from where it is drawn up and blown into the plenum of the re-circulating and exhaust fan(s).

Figure 1. Diagram showing how the negative pressure ensures that all contaminated particles are kept inside the system providing user and product protection.

The bio-dynamic sealing system of the negative pressure plenum ensures that all contaminated particles are kept inside the system and are automatically drawn to the plenum or pressure chamber to be captured by the main re-circulating and exhaust H 14 HEPA/ULPA filters, thus protecting the user, product and environment.

70% of the filtered air is re-circulated (after passing through a H14 HEPA/ULPA filter), an air cleanliness in Class ISO 3, according to ISO 14644-1 laminar flow pattern downwards into the work chamber and the remaining 30% is exhausted to atmosphere through another H14 HEPA/ULPA filter.

Features that should be considered when purchasing a Class II cabinet are safety, cost (both upfront and energy cost) as well as noise and location. The Premium 212 is one of the most energy efficient cabinets in the market with an annual running cost of 0.084kWh meaning a running cost of 17.40 per year. It is also one of the quietest at 42dB meaning a lab with several cabinets side by side can be a relaxing and suitable work area for any kind of experiment. Other features include dimmable LED lighting, magnetic and removable UV sterilising lamp, electronic angled sliding sash and work surface in stainless steel AISI 316L.

At Biopharma we will always provide advise on your requirements. We regularly visit sites to help decisions such as locations and carry out site surveys. Oh and did someone say we also keep stock of most Class II cabinets.References

1. https://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/

Articles are free to download. Please login to read this article or create an account.

View post:
Choosing the right safety cabinet to advance your gene therapy research - Labmate Online

Global Gene Therapy and Antisense Drugs Market: Snapshot

Since an escalating number of patients are being diagnosed with cancer every day, the global demand for gene therapy and antisense drugs is bound to multiply. The growing incidence of health conditions such as Parkinsons disease and high cholesterol is also boosting the demand for gene therapy and antisense drugs. Several new drugs and therapies have been making their debut in the global gene therapy and antisense drugs market of recent.

For instance, in June 2017, it was announced that a group of scientists at the University of Queensland have developed a new technique that is capable of permanently silencing severe allergies triggered by shellfish, peanuts, and venom. The treatment was found to be successful in animal trials. The technique holds considerable potential for treating asthma completely. During the same month, results of another research study for treating multiple myeloma, a type of blood cancer, were announced at a conference held by the American Society of Clinical Oncology. The new CAR-T therapy consists of filtering the blood of the patients in order to eliminate T cells which are then genetically altered and given back to the patients.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=500

However, the difficulty pertaining to the delivery of antisense technology to the brain can present key challenges to the expansion of the global market for gene therapy and antisense drugs. Moreover, the unavoidable toxic aftereffects associated with the technology can also inhibit the growth of the gene therapy and antisense drugs market worldwide. However, the present attempts at developing safe and efficient antisense drugs by several market participants including Ionis Pharmaceuticals, which undertook testing of the technology on transgenic mice, can promote the further expansion of the market.

Global Gene Therapy and Antisense Drugs Market: Overview

Antisense gene therapy is emerging as one of the most beneficial therapeutics for various diseases such as tumors, cancer etc. These newer therapies are based on increased knowledge of molecular events that lead to disordered cellular growth. The therapy involves using a gene silencing technique rather than a gene repairing technique for silencing the genes effect.

The research report is a valuable tool for comprehending the progression of the global gene therapy and antisense drugs market between 2017 and 2025.

Global Gene Therapy and Antisense Drugs Market: Treatment Insights

Antisense drugs attach to the mRNA of a target protein, which inhibits the protein production process. Antisense therapeutics can obstruct the expression of oncogenes and other cancer-related genes that express growth factors. Antisense gene therapy involves the utilization of various therapeutic strategies which requires a clear knowledge of the molecular anatomy of cancer related genes. Antisense gene therapy is used to treat various diseases such as hemorrhagic fever, cancer, cystic fibrosis, renal diseases, HIV/AIDS, spinal muscular atrophy, and cardiovascular diseases.

Global Gene Therapy and Antisense Drugs Market: Market Segmentation

On the basis of therapeutic area, the gene therapy and antisense drugs market is segmented into cancer, anemia, rheumatoid arthritis, cardiovascular diseases, HIV/AIDS, cystic fibrosis, diabetes mellitus and obesity, and renal diseases.

By gene transfer method, ex vivo gene transfer and in vivo gene transfer are the segments of the market. The former involves the transfer of cloned genes into cells, i.e., cells are altered outside the body before being implanted into the patient, whereas the latter involves the transfer of cloned genes directly into the patients tissues. The outcome of in vivo gene transfer technology mainly depends on the general efficacy of gene transfer and expression.

Global Gene Therapy and Antisense Drugs Market: Regional Outlook

The global gene therapy and antisense drugs market is segmented into North America, Asia Pacific, Europe, and Rest of the World. Amongst these, North America holds the leading position in the market followed by Europe. The increasing incidence of cancer and other fatal diseases, unhealthy lifestyle practices such as excessive smoking and excessive consumption of high fat content food, and increasing research efforts for treatment against cancer are the major factors driving the gene therapy and antisense drugs market in these regions.

Asia Pacific is expected to emerge as a significant market for gene therapy and antisense drugs. The high population density including a large geriatric population, expeditiously increasing demand for technologically advanced therapeutics, and increasing government support for improved healthcare infrastructure in the region is driving the growth of this regional market. Furthermore, favorable reimbursement policies and tax benefits on newer therapies will further fuel the growth of the Asia Pacific gene therapy and antisense drugs market.

Major Companies Mentioned in Report

Some of the leading companies operating in the global gene therapy and antisense drugs market are GenVec Inc., Avigen Inc., Genome Therapeutics Corp., Tekmira Pharmaceuticals Corporation, Isis Pharmaceuticals, Cell Genesys Inc., and others. These companies are profiled for their key business attributes in the report.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/gene-therapy-antisense-drugs-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

See the article here:
Gene Therapy And Antisense Drugs Market Newer segments of application 2025 - Cole of Duty

Hemophilia Gene Therapy Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The globalHemophilia Gene Therapy marketshave undergone huge change in the last few months. These changes were due to the outbreak of the pandemic which was first detected in the Wuhan city of China. COVID-19 which has occurred due to the coronavirus has taken many lives of people around the world. As the disease is spreading at a rapid rate many of the countries have ordered lockdown for maintaining social distancing. Due to the lockdown, many of the industries have halted their manufacturing units. There have been restrictions for cross border trading within the countries and also within the states. Owing to these conditions, trading conditions in various regions have been affected badly. The overall countries in the world are facing economic crisis thus affecting some of the major markets in the world.

Request Free Sample Copy of Hemophilia Gene Therapy Market Research Report@http://www.marketresearchstore.com/report/global-hemophilia-gene-therapy-market-report-2019-industry-607887#RequestSample

The research analysts from theMarket Research Storehave conducted a detailed study about the global Hemophilia Gene Therapy market. Owing to the above mentioned conditions, the global Hemophilia Gene Therapy market has undergone several changes on the global platform. All these updates are mentioned in the Hemophilia Gene Therapy market report study. The research analysts have conducted a thorough primary and secondary research for updating the market statistics as per the current market scenario. The detailed Hemophilia Gene Therapy market report is of over 150 pages including more than 30 tables and around 20 figures. The report includes pictorial representations of the market data in order to understand the Hemophilia Gene Therapy market in a simple and easy way.

The data that is included about the Hemophilia Gene Therapy market incorporates historical data from 2016 to 2019 and forecasts data from 2020 to 2026. The major players that are functioning in the Hemophilia Gene Therapy market areSpark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics. Details about all the market players, distributors, suppliers, and retailers are profiled in the Hemophilia Gene Therapy market report.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-hemophilia-gene-therapy-market-report-2019-industry-607887

The Hemophilia Gene Therapy market is segmented into{Hemophilia A, Hemophilia B}; {Hemophilia A Gene Therapy, Hemophilia B Gene Therapy}. Each of the market segments is described in detail within the report. Data about the segments are represented in both qualitative and quantitative format, thus enabling to understand the market in detail.

Major Advantages for Hemophilia Gene Therapy Market:

Well-organized description of the international Hemophilia Gene Therapy market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Hemophilia Gene Therapy industry. The Hemophilia Gene Therapy market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Hemophilia Gene Therapy market. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of Hemophilia Gene Therapy Report:http://www.marketresearchstore.com/report/global-hemophilia-gene-therapy-market-report-2019-industry-607887#InquiryForBuying

Link:
Global Hemophilia Gene Therapy Market 2020 with COVID-19 After Effects Analysis by Key Players | Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo...

A new research study has been presented by Industrygrowthinsights.com offering a comprehensive analysis on the Global Gene Therapy Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Gene Therapy Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Gene Therapy Market Report with Latest Industry Trends @ https://industrygrowthinsights.com/request-sample/?reportId=137776

Major Players Covered in this Report are: SangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVicalAdvantagene

Global Gene Therapy Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:Ex vivoIn vivo

By Applications:Cancer DiseasesMonogenic DiseasesInfectious DiseasesCardiovascular DiseasesOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=137776

Global Gene Therapy Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Gene Therapy on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Gene Therapy sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Gene Therapy sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=137776

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About Industrygrowthinsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, US.Phone No: US: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://Industrygrowthinsights.com

Original post:
Gene Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions - Bulletin...

New Jersey, United States,- The report is a must-have for business strategists, participants, consultants, researchers, investors, entrepreneurs, and other interested parties associated with the Gene Therapy Market. It is also a highly useful resource for those looking to foray into the Gene Therapy market. Besides Porters Five Forces and SWOT analysis, it offers detailed value chain assessment, comprehensive study on market dynamics including drivers, restraints, and opportunities, recent trends, and industry performance analysis. Furthermore, it digs deep into critical aspects of key subjects such as market competition, regional growth, and market segmentation so that readers could gain sound understanding of the Gene Therapy market.

The research study is a brilliant account of macroeconomic and microeconomic factors influencing the growth of the Gene Therapy market. This will help market players to make appropriate changes in their approach toward attaining growth and sustaining their position in the industry. The Gene Therapy market is segmented as per type of product, application, and geography. Each segment is evaluated in great detail so that players can focus on high-growth areas of the Gene Therapy market and increase their sales growth. Even the competitive landscape is shed light upon for players to build powerful strategies and give a tough competition to other participants in the Gene Therapy market.

The competitive analysis included in the report helps readers to become aware of unique characteristics of the vendor landscape and crucial factors impacting the market competition. It is a very important tool that players need to have in their arsenal for cementing a position of strength in the Gene Therapy market. Using this report, players can use effective business tactics to attract customers and improve their growth in the Gene Therapy market. The study provides significant details about the competitive landscape and allows players to prepare for future challenges beforehand.

Gene Therapy Market Segmentation

This market has been divided into types, applications and regions. The growth of each segment provides a precise calculation and forecast of sales by type and application, in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting qualified niche markets. . Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. Research analysts understand competitive forces and provide competitive analysis for each competitor separately.

Gene Therapy Market by Type:

YYYY

Gene Therapy Market by Application:

ZZZZ

Gene Therapy Market by Region:

North America (The USA, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of Europe)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

The report answers important questions that companies may have when operating in the Gene Therapy market. Some of the questions are given below:

What will be the size of the Gene Therapy market in 2026?

What is the current CAGR of the Gene Therapy market?

What products have the highest growth rates?

Which application is projected to gain a lions share of the Gene Therapy market?

Which region is foretold to create the most number of opportunities in the Gene Therapy market?

Which are the top players currently operating in the Gene Therapy market?

How will the market situation change over the next few years?

What are the common business tactics adopted by players?

What is the growth outlook of the Gene Therapy market?

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40223&utm_source=COD&utm_medium=002

Reasons to Buy the Report

Upgrade your market research resources with this comprehensive and accurate report on the Gene Therapy market

Get complete understanding of general market scenarios and future market situations to prepare for rising above the challenges and ensuring strong growth

The report offers in-depth research and various tendencies of the Gene Therapy market

It provides detailed analysis of changing market trends, current and future technologies used, and various strategies adopted by leading players of the Gene Therapy market

It offers recommendations and advice for new entrants of the Gene Therapy market and carefully guides established players for further market growth

Apart from hottest technological advances in the Gene Therapy market, it brings to light the future plans of dominant players in the industry

Table of Contents

Market Overview: This section comes under executive summary and is divided into four sub-sections. It basically introduces the Gene Therapy market while focusing on market size by revenue and production, market segments by type, application, and region, and product scope.

Competition by Manufacturers: It includes five sub-sections, viz. market competitive situation and trends, manufacturers products, areas served, and production sites, average price by manufacturers, revenue share by manufacturers, and production share by manufacturers.

Market Share by Region: It provides regional market shares by production and revenue besides giving details about gross margin, price, and other factors related to the growth of regional markets studied in the report. The review period considered here is 2015-2019.

Company Profiles: Each player is assessed for its market growth in terms of different factors such as markets served, gross margin, price, revenue, production, product specification, and areas served.

Manufacturing Cost Analysis: It is sub-divided into four chapters, viz. industrial chain analysis, manufacturing process analysis, manufacturing cost structure, and key raw materials analysis.

Learn More about this report @ https://www.verifiedmarketresearch.com/product/gene-therapy-market/?utm_source=COD&utm_medium=002

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart City ICT Infrastructure Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:
Gene Therapy Market 2020 Key Players, Share, Trend, Segmentation and Forecast to 2026 - Cole of Duty

Cell Therapy Manufacturing Market 2020 Global Industry Research report presents an in-depth analysis of the Cell Therapy Manufacturing market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2027 forecast.

Global Cell Therapy Manufacturing Market 2020 Industry Research Report is an expert and inside and out examination on the flow condition of the Global Cell Therapy Manufacturing industry. In addition, investigate report sorts the worldwide Cell Therapy Manufacturing market by top players/brands, area, type and the end client. This report likewise examines the different Factors impacting the market development and drivers, further reveals insight into market review, key makers, key received by them, size, most recent patterns and types, income, net edge with provincial examination and figure.

Read Summary Of Cell Therapy Manufacturing Market Report @Cell Therapy Manufacturing Market

List Of TOP KEY PLAYERS in Cell Therapy Manufacturing Market are: Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Scope of Report:

The global Cell Therapy Manufacturing market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2027. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

This report covers present status and future prospects for the Cell Therapy Manufacturing Market forecast till 2027. Market Overview, Development, and Segment by Type, Application and Region. Global Market by company, Type, Application and Geography. The report begins with an overview of the industry chain structure and describes the upstream. Besides, the report analyses Cell Therapy Manufacturing market trends, size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Cell Therapy Manufacturing Market Research Report provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

We do offer sample of this report. Kindly go through the follow information in order to access sample copy.

Get Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/1728

This report sample includes

Brief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

Cell Therapy Manufacturing Market global industry research report is a professional and in-depth study on the market size, growth, share, trends, as well as industry analysis. According to the details of the consumption figures, the global Cell Therapy Manufacturing market forecast 2027.

Market by Region:

North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)The Middle East and Africa (Saudi Arabia, South Africa etc.)

Key Benefits For Stakeholders

Cell Therapy Manufacturing Market Taxonomy

On the basis of therapy type, the global cell therapy manufacturing market is segmented into:

On the basis of technology, the global cell therapy manufacturing market is segmented into:

On the basis of source, the global cell therapy manufacturing market is segmented into:

On the basis of application, the global cell therapy manufacturing market is segmented into:

On the basis of region, the global cell therapy manufacturing market is segmented into:

Main Aspects Covered In The Report:

Overview of the Cell Therapy Manufacturing market including production, consumption, status and forecast and market growth.Geographical analysis including major countries.Overview of the product type market including development.Overview of the end-user market including development.

Research Objectives:

To understand the structure of Cell Therapy Manufacturing market by identifying its various sub-segments.Focuses on the key global Cell Therapy Manufacturing manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Cell Therapy Manufacturing with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Cell Therapy Manufacturing submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

Request Discount option enables you to get discounts on the actual price of the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss your allocated budget and would provide discounts.

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask Discount Before Purchasing @ https://www.coherentmarketinsights.com/insight/request-discount/1728

At last, the report gives the inside and out examination of Cell Therapy Manufacturing Market took after by the above components, which are useful for organizations or individuals for the development of their present business or the individuals who are hoping to enter in Cell Therapy Manufacturing industry.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Read the original post:
Cell Therapy Manufacturing Market: Factory Price and Marginal Revenue Analysis by 2026 - Surfacing Magazine

Application of ImmTOR plus Sareptas investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies

CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences, Inc. (SELB) today announced that they have entered into a Research License and Option agreement granting Sarepta an option to license the rights to develop and commercialize Selectas immune tolerance platform, ImmTOR, for use in Duchenne muscular dystrophy (DMD) and certain limb-girdle muscular dystrophies (LGMDs). In advance of exercising its option, Sarepta will conduct research and evaluate the utility of ImmTOR to minimize or prevent the formation of neutralizing antibodies (NAb) to adeno-associated virus (AAV) in connection with the administration of Sareptas DMD and LGMD gene therapy candidates.

Sareptas late-stage gene therapy candidates are delivered using AAV in particular, AAVrh74. AAVrh74 was selected because of its safety profile, superior muscle tropism, empirical demonstration of high expression, and low screen-out rate for pre-existing antibodies. Currently, however, all systemic AAV-delivered constructs are one-time therapies that cannot be re-dosed due to the robust post-administration development of NAbs specific to the AAV vector. Selecta is a leader in immune tolerance and has generated strong preclinical evidence to support the potential for re-dosing patients receiving gene therapy.Selecta has reported that in preclinical studies, when used in combination with AAV gene therapy vectors,Selectas ImmTOR immune tolerance platform inhibits the development of NAbs to the vector, permitting re-dosing of the gene therapy. i

As we build our enduring gene therapy engine, we intend not only to rapidly advance treatments for rare, life-ending diseases, but at the same time, to advance the state of genetic medicine science by continually improving the utility of gene therapy. If successful, the ability to re-dose will be an enormous leap forward in the science of gene therapy and provide invaluable benefits to patients beyond those we anticipate with one-time dosing. We are encouraged by the data generated on the ImmTOR platform and excited to join with Selecta to explore the possibility of unlocking the opportunity to safely and effectively re-dose AAV-mediated gene therapies in patients with DMD and LGMDs, if needed, said Doug Ingram, President and Chief Executive Officer, Sarepta Therapeutics.

We are pleased to build on our already strong foundation of strategic partnerships and expand the clinical application of the ImmTOR platform into neuromuscular diseases. The ability to re-dose gene therapy addresses one of the major challenges of one-time therapies today, said Carsten Brunn Ph.D., President and Chief Executive Officer of Selecta Biosciences. We are excited to collaborate with a leader in genetic medicine like Sarepta, and are confident that their expertise in rare diseases combined with our immune tolerance platform has the potential to enhance the long-term therapeutic benefit to patients with these debilitating conditions.

DMD is a rare, degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. LGMDs are a group of over 30 distinct diseases that cause weakness and wasting of the muscles around the hips and shoulders, eventually progressing to the arms and legs. LGMD can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact.

Under the terms of the research license and option agreement, Sarepta will make an initial payment to Selecta, and Selecta is eligible to receive certain pre-clinical milestone fees. If Sarepta exercises its options to enter any commercial license agreements, Selecta will be eligible for additional development, regulatory, and commercial milestone payments, as well as tiered royalties on net product sales. Additional financial details are not being disclosed.

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its pioneering immune tolerance platform (ImmTOR). Selecta is committed to utilizing ImmTOR to potentially improve the efficacy of biologics, enable re-dosing of life-saving gene therapy, and create novel immunotherapies for autoimmune diseases. Selectas late-stage product candidate, SEL-212, is designed to be a monthly treatment for chronic refractory gout, a debilitating rare disease with a significant unmet medical need. SEL-212 consists of a combination of our ImmTOR platform co-administered with pegadricase, an enzyme designed to treat patients with symptomatic gout, refractory to standard uric acid lowering treatment. Selectas proprietary gene therapy product candidates are in development for certain rare inborn errors of metabolism and incorporate our ImmTOR platform with the goal of addressing barriers to repeat administration. In addition to our own pipeline of core discovery and clinical candidates, Selecta has established collaborative relationships with leading biopharmaceutical companies, including Asklepios BioPharmaceutical (AskBio) for gene therapy, and Swedish Orphan Biovitrum AB (Sobi) for SEL-212. Selecta is based in Watertown, Massachusetts. For more information, please visit http://www.selectabio.com.

Story continues

Selecta Forward-Looking Statements:

Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the company), including without limitation, the companys actions regarding the monitoring and assessment of COVID-19 on the companys operations, clinical trials and manufacturing, Sareptas plans to evaluate its gene therapies in combination with the companys ImmTOR technology, the possibility of Sarepta exercising an option to enter into a commercial license agreement, the unique proprietary technology platform of the company and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy, the ability of the companys ImmTOR platform to unlock the full potential of biologic therapies, the potential treatment applications for product candidates utilizing the ImmTOR platform in areas such as enzyme therapy and gene therapy, the novelty of treatment paradigms that Sarepta is able to develop in combination with the companys ImmTOR technology, the potential of any therapies developed by Sarepta in combination with the companys ImmTOR technology to fulfill unmet medical needs, the companys plan to apply its ImmTOR technology platform to a range of biologics for rare and serious diseases, the ability of Sareptas existing therapies to target the heart and skeletal muscle, expected payments to be made to the company under the Research License and Option Agreement, the potential of the ImmTOR technology platform generally and the companys ability to grow its strategic partnerships, the sufficiency of the companys cash, cash equivalents and short-term investments, and other statements containing the words anticipate, believe, continue, could, estimate, expect, hypothesize, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the effect of the COVID-19 outbreak on any of the companys planned or ongoing clinical trials, manufacturing activities, supply chain and operations, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the unproven approach of the companys ImmTOR technology, Sareptas ability to research and develop therapeutic candidates using the companys ImmTOR technology, undesirable side effects of the companys product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials as well as the impact of the COVID-19 outbreak on those third parties and their ability to continue their operations, the companys inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, managements ability to perform as expected, potential delays in regulatory approvals, Sareptas ability to make up-front and milestone payments, the companys business development strategy, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the companys recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock including stock market fluctuations that occur as a result of the COVID-19 outbreak, and other important factors discussed in the Risk Factors section of the companys most recent Quarterly Report on Form 10-Q, and in other filings that the company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the companys views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any intention to update any forward-looking statements included in this press release.

AboutSarepta Therapeutics

At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.comor follow us onTwitter,LinkedIn,InstagramandFacebook.

Sarepta Forward-Looking Statement

This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the parties undertakings under the agreement and potential payments and fees; the potential benefits of Sareptas gene therapy product candidates; the potential of ImmTOR to enable re-dosing of AAV gene therapy; Sareptas intention to rapidly advance treatments for rare, life-ending diseases, and to advance the state of the genetic medicine science by continually improving the utility of gene therapy; the potential of re-dosing to provide invaluable benefits to patients beyond those Sarepta anticipates with one-time dosing; the possibility of unlocking the opportunity to safely and effectively re-dose AAV-mediated gene therapies in patients with DMD and LGMDs, if needed; and the potential of the collaboration between Sarepta and Selecta to enhance the long-term therapeutic benefit to patients with these debilitating conditions.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Known risk factors include, among others: the expected benefits and opportunities related to the collaboration between Sarepta and Selecta may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development. In particular, the collaboration may not result in any viable treatments suitable for commercialization due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement; success in preclinical trials does not ensure that later clinical trials will be successful; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and even if Sareptas programs result in new commercialized products, Sarepta may not achieve the expected revenues from the sale of such products; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Selecta Contacts:For Media:Joshua R. MansbachSolebury Trout+1-646-378-2964jmansbach@soleburytrout.com

For Investors:Lee M. SternSolebury Trout+1-646-378-2922lstern@soleburytrout.com

Sarepta Contacts: Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

i Nature Communications,October 2018.

Original post:
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selectas ImmTOR Immune Tolerance Platform in...

The Gene Therapy Products Market report is a truthful source of information which offers a telescopic view of the current market trends, situations, opportunities and status. All the data and information collected in this market document for research and analysis is represented in the form of graphs, charts or tables for the sensible understanding of users. Besides, big sample sizes have been exploited for the data collection in this report which ensembles the necessities of small, medium as well as large size of businesses. This Gene Therapy Products Market analysis report works on all the aspects of market that are required to create the finest and top-notch market research report.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-gene-therapy-products-market

Increasing prevalence of Gene Therapy Products Market report highlights the notable industry growth drivers, challenges, opportunities and restraints for the leading key players. This market research report assesses in progress as well as future performance of the market in addition to brand-new trends in the market. This market research report also identifies and analyses the emerging trends along with major driving factors, challenges and opportunities in the market. The report includes market shares for global, Europe, North America, Asia Pacific and South America. The global Gene Therapy Products Market business report is a great resource which provides current and upcoming technical and financial details of the industry.

Global gene therapy products market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cancer cases and unused potential for emerging markets are the major factors for the growth of this market.

Few of the major competitors currently working in the globalgene therapy products marketareAdaptimmune., Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION, GlaxoSmithKline plc., Merck KGaA, Novartis AG, Achieve Life Sciences, Inc., Spark Therapeutics, Inc., Abeona Therapeutics, Inc, Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics, AveXis, Inc., CRISPR Therapeutics, Intellia Therapeutics, Inc and Gilead Sciences,Inc. among others.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-gene-therapy-products-market

Market Definition:Global Gene Therapy Products Market

Gene therapy or human gene therapy is a process which is used to modify gene for the treatment of any disease. Plasmid DNA, bacterial vector, human gene editing technology and viral vectors are some of the most common type of gene therapy products. The main aim of the gene therapy is to replace the dysfunctional genes. Somatic and germline are some of the most common type of the gene therapy.

Segmentation: Global Gene Therapy Products Market

Gene Therapy Products Market : By Product

Gene Therapy Products Market : By Application

Gene Therapy Products Market : ByGeography

Key Developments in the Gene Therapy Products Market:

Gene Therapy Products Market Drivers

Gene Therapy Products Market Restraints

Competitive Analysis: Gene Therapy Products Market

Global gene therapy products market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of gene therapy products market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key questions answered in the report :-

To get this report at an attractive cost, click herehttps://www.databridgemarketresearch.com/speak-to-analyst?dbmr=global-gene-therapy-products-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

Originally posted here:
Gene Therapy Products Market 2020 Global Industry Trends and Forecast | Major Players are Adverum, agtc, Arbutus Biopharma, Audentes Therapeutics,...

Global Gene Therapy for Age-related Macular Degeneration Market Research Report Cover Covid-19 Impact

The Gene Therapy for Age-related Macular Degeneration market research report fabricated by Brand Essence Market Research is an in-depth analysis of the latest trends persuading the business outlook. The report also offers a concise summary of statistics, market valuation, and profit forecast, along with elucidating paradigms of the evolving competitive environment and business strategies enforced by the behemoths of this industry.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=11998&RequestType=Sample

Latest research report on Gene Therapy for Age-related Macular Degeneration Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the markets growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study RetroSense Therapeutics REGENXBIO AGTC

Market segment by Type, the product can be split into Subretinal Intravitreal Unspecified

Market segment by Application, split into Monotherapy Combination Therapy

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Request Customization of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=11998&RequestType=Customization

Key Reasons to Purchase:

To gain insightful analyses of the market and a comprehensive understanding of the impact of COVID-19 is likely to have on the Gene Therapy for Age-related Macular Degeneration Market during the forecast period between 2020 and 2026, and its commercial landscapeTo learn about the market strategies that are being adopted by your competitors and other leading companiesTo understand the future outlook and prospects of the Gene Therapy for Age-related Macular Degeneration Market post COVID-19To keep you abreast with the strategies used by other players in theTo understand the changes in rules and regulations in various countries during COVID-19 and its possible effects on the market in the future.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Here is the original post:
What's Driving on Gene Therapy for Age-related Macular Degeneration Market 2020 by Product, Application, Manufacturer, Sales and Segmentation 2025 -...